{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-089277","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.413491+00:00","generated_at":"2026-05-31T13:48:18.425677+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M","bullets":["Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.","Surgical Glaucoma revenue $20.2M (-5% YoY); Dry Eye revenue $1.1M (-46% YoY).","Cash used improved to $9.1M from $12.8M in Q2 2023; cash and equivalents $118.2M.","Narrowed FY2024 revenue guidance to $81M-$83M (0-2% growth) from prior $81M-$85M; adj. op. expenses $107M-$109M.","CMS proposes device-intensive status for OMNI procedure, which could increase ASC facility fee 29% in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-089277","json":"https://secwatch.observer/filing/0000950170-24-089277.json","markdown":"https://secwatch.observer/filing/0000950170-24-089277.md","text":"https://secwatch.observer/filing/0000950170-24-089277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/0000950170-24-089277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/sght-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:48:18.425677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}